TY - JOUR

T1 - Incidence of dyslipidemia in people with HIV who are treated with integrase inhibitors versus other antiretroviral agents

AU - Byonanebye, Dathan M.

AU - Polizzotto, Mark N.

AU - Begovac, Josip

AU - Grabmeier-Pfistershammer, Katharina

AU - Abela, Irene

AU - Castagna, Antonella

AU - de Wit, Stéphane

AU - Mussini, Cristina

AU - Vehreschild, Jörg J.

AU - d'Arminio Monforte, Antonella

AU - Wit, Ferdinand W.N.M.

AU - Pradier, Christian

AU - Chkhartishvili, Nikoloz

AU - Sönnerborg, Anders

AU - Hoy, Jennifer

AU - Lundgren, Jens

AU - Neesgaard, Bastian

AU - Bansi-Matharu, Loveleen

AU - Greenberg, Lauren

AU - Llibre, Josep M.

AU - Vannappagari, Vani

AU - Gallant, Joel

AU - Necsoi, Coca

AU - Cichon, Piotr

AU - Reiss, Peter

AU - Aho, Inka

AU - Tsertsvadze, Tengiz

AU - Mennozzi, Marianna

AU - Rauch, Andri

AU - Muccini, Camilla

AU - Law, Matthew

AU - Mocroft, Amanda

AU - Ryom, Lene

AU - Petoumenos, Kathy

AU - Hillebregt, M.

AU - Rose, N.

AU - Zangerle, R.

AU - Appoyer, H.

AU - Delforge, M.

AU - Wandeler, Gilles

AU - Stephan, C.

AU - Bucht, M.

AU - Chokoshvili, O.

AU - Rodano, A.

AU - Tavelli, A.

AU - Fanti, I.

AU - Borghi, V.

AU - Fontas, E.

AU - Dollet, K.

AU - Caissotti, C.

AU - The Respond Study Group

N1 - Publisher Copyright: Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.

PY - 2021

Y1 - 2021

N2 - Objective: To compare the incidence of dyslipidemia in people with HIV receiving integrase inhibitors (INSTI) versus boosted protease inhibitors (PI/b) and nonnucleoside reverse transcriptase inhibitors (NNRTI) within RESPOND consortium of prospective cohorts. Methods: Participants were eligible if they were at least 18 years, without dyslipidemia and initiated or switched to a three-drug antiretroviral therapy (ART)-regimen consisting of either INSTI, NNRTI, or PI/b for the first time, between 1 January 2012 and 31 December 2018. Dyslipidemia was defined as random total cholesterol more than 240 mg/dl, HDL less than 35 mg/dl, triglyceride more than 200 mg/dl, or initiation of lipid-lowering therapy. Poisson regression was used to determine the adjusted incidence rate ratios. Follow-up was censored after 3 years or upon ART-regimen discontinuation or last lipid measurement or 31 December 2019, whichever occurred first. Results: Overall, 4577 people with HIV were eligible (INSTI = 66.9%, PI/b = 12.5%, and NNRTI = 20.6%), 1938 (42.3%) of whom were ART-naive. During 1.7 (interquartile range, 0.6 - 3.0) median years of follow-up, 1460 participants developed dyslipidemia [incidence rate: 191.6 per 1000 person-years, 95% confidence interval (CI) 182.0 - 201.7]. Participants taking INSTI had a lower incidence of dyslipidemia compared with those on PI/b (adjusted incidence rate ratio 0.71; CI 0.59 - 0.85), but higher rate compared with those on NNRTI (1.35; CI 1.15 - 1.58). Compared with dolutegravir, the incidence of dyslipidemia was higher with elvitegravir/cobicistat (1.20; CI 1.00 - 1.43) and raltegravir (1.24; CI 1.02 - 1.51), but lower with rilpivirine (0.77; CI 0.63 - 0.94). Conclusion: In this large consortium of heterogeneous cohorts, dyslipidemia was less common with INSTI than with PI/b. Compared with dolutegravir, dyslipidemia was more common with elvitegravir/cobicistat and raltegravir, but less common with rilpivirine.

AB - Objective: To compare the incidence of dyslipidemia in people with HIV receiving integrase inhibitors (INSTI) versus boosted protease inhibitors (PI/b) and nonnucleoside reverse transcriptase inhibitors (NNRTI) within RESPOND consortium of prospective cohorts. Methods: Participants were eligible if they were at least 18 years, without dyslipidemia and initiated or switched to a three-drug antiretroviral therapy (ART)-regimen consisting of either INSTI, NNRTI, or PI/b for the first time, between 1 January 2012 and 31 December 2018. Dyslipidemia was defined as random total cholesterol more than 240 mg/dl, HDL less than 35 mg/dl, triglyceride more than 200 mg/dl, or initiation of lipid-lowering therapy. Poisson regression was used to determine the adjusted incidence rate ratios. Follow-up was censored after 3 years or upon ART-regimen discontinuation or last lipid measurement or 31 December 2019, whichever occurred first. Results: Overall, 4577 people with HIV were eligible (INSTI = 66.9%, PI/b = 12.5%, and NNRTI = 20.6%), 1938 (42.3%) of whom were ART-naive. During 1.7 (interquartile range, 0.6 - 3.0) median years of follow-up, 1460 participants developed dyslipidemia [incidence rate: 191.6 per 1000 person-years, 95% confidence interval (CI) 182.0 - 201.7]. Participants taking INSTI had a lower incidence of dyslipidemia compared with those on PI/b (adjusted incidence rate ratio 0.71; CI 0.59 - 0.85), but higher rate compared with those on NNRTI (1.35; CI 1.15 - 1.58). Compared with dolutegravir, the incidence of dyslipidemia was higher with elvitegravir/cobicistat (1.20; CI 1.00 - 1.43) and raltegravir (1.24; CI 1.02 - 1.51), but lower with rilpivirine (0.77; CI 0.63 - 0.94). Conclusion: In this large consortium of heterogeneous cohorts, dyslipidemia was less common with INSTI than with PI/b. Compared with dolutegravir, dyslipidemia was more common with elvitegravir/cobicistat and raltegravir, but less common with rilpivirine.

U2 - 10.1097/QAD.0000000000002811

DO - 10.1097/QAD.0000000000002811

M3 - Journal article

C2 - 33443370

AN - SCOPUS:85104047208

VL - 35

SP - 869

EP - 882

JO - AIDS

JF - AIDS

SN - 1350-2840

IS - 6

ER -